Emergent BioSolutions Inc
NYSE:EBS
Emergent BioSolutions Inc
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,416 full-time employees. The company went IPO on 2006-11-15. The firm is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. The company provides solutions for public health threats through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The firm also offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers.
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 2,416 full-time employees. The company went IPO on 2006-11-15. The firm is focused on five PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases; travel health; public health crises (such as the opioid crisis and the COVID-19 pandemic); acute, emergency, and community care. Its business lines include Medical Countermeasures (MCM), Commercial and CDMO. MCM focuses primarily on procurement of MCM products and procured product candidates by domestic and international government customers. The company provides solutions for public health threats through a portfolio of vaccines and therapeutics that it develops and manufactures for governments and consumers. The firm also offers a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers.
Revenue Beat: Q3 revenue was $231 million, exceeding the top end of guidance by $21 million and analyst consensus.
Profitability: Adjusted EBITDA margin reached 38% for the quarter, with net income of $51 million.
Guidance Raised: Full-year revenue guidance increased to $775–835 million and adjusted EBITDA to $195–210 million.
Strong Cash Position: Liquidity totaled $346 million, and net leverage improved to 2x adjusted EBITDA.
Naloxone Growth: NARCAN unit volume grew 13% and revenue grew 9% quarter-over-quarter; market conditions remain favorable.
International Sales: International customers drove 34% of MCM sales year-to-date, up significantly from prior years.
Operational Efficiency: SG&A spending dropped by roughly 50% year-over-year, and gross margin improved by 200 basis points.
